キイトルーダの世界市場レポート 2024

キイトルーダ市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は9.9%で315億2,000万米ドルに成長します。予測期間中に予想される成長は、キイトルーダ（ペムブロリズマブ）の適応拡大、がん治療の新興市場、がん患者の有病率の増加、世界のヘルスケア支出の増加、腫瘍学における精密医療への需要の高まりなど、いくつかの要因に起因すると考えられます。この期間に予想される主な動向には、キイトルーダのような標的治療薬に対する需要の高まり、免疫療法アプローチの進歩、がんの検出とモニタリングのための診断技術の革新、効果的ながん治療に対する需要の急増、がん研究における継続的な進歩などがあります。

キイトルーダ市場の成長は、がんの有病率の増加によって推進されると予想されます。がんは、細胞の異常な増殖と拡散を特徴とする複雑な疾患群であり、遺伝的要因、ライフスタイル要因、環境要因、ホルモン要因の影響を受ける。キイトルーダ（ペムブロリズマブ）は、がん細胞とより効果的に闘うために身体の免疫システムを活用することにより、がん治療において重要な役割を果たしています。これは、がん細胞を標的として攻撃する免疫系の能力を活用することによるがん治療の大きな進歩であり、進行がんや転移性がんの患者に新たな希望を提供するものです。例えば、国立医学図書館によれば、2040年には世界のがん罹患者数は2,840万人に達すると予測されており、これは2020年から47％の増加です。このように、がんの有病率の上昇がキイトルーダ市場の原動力となっています。

キイトルーダ市場の大手企業は、治療の選択肢を広げるため、ペムブロリズマブなどの革新的な製品の開発に注力しています。ペムブロリズマブは免疫チェックポイント阻害薬に属するモノクローナル抗体医薬品で、キイトルーダという商品名で販売されています。T細胞として知られる免疫細胞上のPD-1（プログラム細胞死タンパク質1）と呼ばれるタンパク質を標的とし、阻害します。例えば、2023年11月、米国の製薬会社であるメルク社は、キイトルーダ（ペムブロリズマブ）を、FDA（米国食品医薬品局）により承認されたフルオロピリミジンおよびプラチナを含む化学療法との併用療法として発売しました。この併用療法は、化学療法単独と比較して全生存期間および無増悪生存期間において有意な改善を示しており、胃がん治療における有望な進歩です。臨床試験では、単独の化学療法と比較して、全生存期間（OS）、無増悪生存期間（PFS）、全奏効率（ORR）の向上が証明されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のキイトルーダ市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のキイトルーダ市場の実績：規模と成長, 2018-2023
• 世界のキイトルーダ市場の予測：規模と成長, 2023-2028, 2033F

第6章 市場セグメンテーション

• 世界のキイトルーダ市場がんの種類別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 悪性黒色腫
• 肺がん
• 頭頸部がん
• ホジキンリンパ腫
• 胃がん
• 尿路上皮がん
• 世界のキイトルーダ市場：支払者タイプ別、実績と予測, 2018-2023, 2023-2028F, 2033F
• コマーシャル
• メディケア
• メディケイド
• 世界のキイトルーダ市場：流通チャネル別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 病院薬局
• 専門薬局

第7章 地域別・国別分析

• 世界のキイトルーダ市場：地域別、実績と予測, 2018-2023, 2023-2028F, 2033F
• 世界のキイトルーダ市場：国別、実績と予測, 2018-2023, 2023-2028F, 2033F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• キイトルーダ市場：競合情勢
• キイトルーダ市場：企業プロファイル
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Roche Holding AG
  • Merck & Co. Inc.
  • AbbVie Inc.

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Novartis AG
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• BioNTech AG
• Organon Co.
• Ono Pharmaceutical Co. Ltd.
• Samsung Bioepis Co. Ltd.
• Fate Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

Keytruda, also known as pembrolizumab, is a monoclonal antibody medication utilized in cancer treatment. It falls under the category of immune checkpoint inhibitors, working by targeting and blocking the PD-1 (programmed cell death protein 1) protein in immune cells. This action assists the immune system in recognizing and attacking cancer cells effectively.

Keytruda is primarily used in treating various cancer types, including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma. Melanoma, specifically, is a type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment giving skin its color. The medication is available through different payer types such as commercial, Medicare, and Medicaid, and distributed through various channels such as hospital pharmacies and specialty pharmacies.

The keytruda market research report is one of a series of new reports from The Business Research Company that provides keytruda market statistics, including keytruda industry global market size, regional shares, competitors with a keytruda market share, detailed keytruda market segments, market trends and opportunities, and any further data you may need to thrive in the keytruda industry. This keytruda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The keytruda market size has grown strongly in recent years. It will grow from $19.71 billion in 2023 to $21.60 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historic period can be attributed to several factors, including improved patient outcomes, increased adoption of immunotherapy in cancer treatment, ongoing research and development efforts, enhanced patient compliance with treatments, and increased adoption of Keytruda (pembrolizumab) as a medication for cancer therapy.

The keytruda market size is expected to see strong growth in the next few years. It will grow to $31.52 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The expected growth in the forecast period can be attributed to several factors, including expanding indications for Keytruda (pembrolizumab), emerging markets for cancer treatments, the increasing prevalence of cancer cases, rising healthcare expenditure globally, and the growing demand for precision medicine in oncology. Major trends anticipated during this period include a heightened demand for targeted therapies such as Keytruda, advancements in immunotherapy approaches, innovations in diagnostic technologies for cancer detection and monitoring, a surge in demand for effective cancer treatments, and ongoing advancements in cancer research.

The growth of the Keytruda market is expected to be propelled by the increasing prevalence of cancer. Cancer, a complex group of diseases characterized by abnormal cell growth and spread, is influenced by genetic, lifestyle, environmental, and hormonal factors. Keytruda (pembrolizumab) plays a crucial role in cancer treatment by leveraging the body's immune system to combat cancer cells more effectively. This represents a significant advancement in cancer treatment by harnessing immune system capabilities to target and attack cancer cells, offering new hope to patients with advanced or metastatic cancers. For example, according to the National Library of Medicine, the global cancer burden is projected to reach 28.4 million cases in 2040, marking a 47% increase from 2020. Thus, the rising prevalence of cancer is a driving force behind the Keytruda market.

Leading companies in the Keytruda market are focused on developing innovative products such as pembrolizumab to expand treatment options. Pembrolizumab, a monoclonal antibody medication belonging to immune checkpoint inhibitors, is marketed under the brand name Keytruda. It targets and inhibits a protein called PD-1 (programmed cell death protein 1) on immune cells known as T cells. For instance, in November 2023, Merck, a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy approved by the Food and Drug Administration (FDA). This combination therapy has shown significant improvements in overall survival and progression-free survival compared to chemotherapy alone, presenting a promising advancement in gastric cancer treatment. Clinical trials have demonstrated enhancements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to standalone chemotherapy.

In May 2024, CytomX Therapeutics, a US-based biotechnology company, partnered with Merck to assess CX-801 with KEYTRUDA (pembrolizumab) in patients with advanced metastatic solid tumors. This collaboration aims to evaluate the safety, tolerability, and preliminary efficacy of CX-801 in combination with KEYTRUDA for advanced metastatic solid tumors. Merck, a US-based company, offers Keytruda as part of its pharmaceutical portfolio.

Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.

North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the keytruda market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The keytruda market consists of sales of immunotherapy, combination therapies, clinical trials, and personalized medicine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Keytruda Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on keytruda market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for keytruda ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The keytruda market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Melanoma; Lung Cancer; Head And Neck Cancer; Hodgkin Lymphoma; Stomach Cancer; Urothelial Carcinoma
• 2) By Payer Type: Commercial; Medicare; Medicaid
• 3) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Keytruda Market Characteristics

3. Keytruda Market Trends And Strategies

4. Keytruda Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Keytruda Market Size and Growth

• 5.1. Global Keytruda Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Keytruda Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Keytruda Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Keytruda Market Segmentation

• 6.1. Global Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Melanoma
• Lung Cancer
• Head And Neck Cancer
• Hodgkin Lymphoma
• Stomach Cancer
• Urothelial Carcinoma
• 6.2. Global Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Commercial
• Medicare
• Medicaid
• 6.3. Global Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Specialty Pharmacies

7. Keytruda Market Regional And Country Analysis

• 7.1. Global Keytruda Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Keytruda Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Keytruda Market

• 8.1. Asia-Pacific Keytruda Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Keytruda Market

• 9.1. China Keytruda Market Overview
• 9.2. China Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Keytruda Market

• 10.1. India Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Keytruda Market

• 11.1. Japan Keytruda Market Overview
• 11.2. Japan Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Keytruda Market

• 12.1. Australia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Keytruda Market

• 13.1. Indonesia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Keytruda Market

• 14.1. South Korea Keytruda Market Overview
• 14.2. South Korea Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Keytruda Market

• 15.1. Western Europe Keytruda Market Overview
• 15.2. Western Europe Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Keytruda Market

• 16.1. UK Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Keytruda Market

• 17.1. Germany Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Keytruda Market

• 18.1. France Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Keytruda Market

• 19.1. Italy Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Keytruda Market

• 20.1. Spain Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Keytruda Market

• 21.1. Eastern Europe Keytruda Market Overview
• 21.2. Eastern Europe Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Keytruda Market

• 22.1. Russia Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Keytruda Market

• 23.1. North America Keytruda Market Overview
• 23.2. North America Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Keytruda Market

• 24.1. USA Keytruda Market Overview
• 24.2. USA Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Keytruda Market

• 25.1. Canada Keytruda Market Overview
• 25.2. Canada Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Keytruda Market

• 26.1. South America Keytruda Market Overview
• 26.2. South America Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Keytruda Market

• 27.1. Brazil Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Keytruda Market

• 28.1. Middle East Keytruda Market Overview
• 28.2. Middle East Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Keytruda Market

• 29.1. Africa Keytruda Market Overview
• 29.2. Africa Keytruda Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Keytruda Market, Segmentation By Payer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Keytruda Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Keytruda Market Competitive Landscape And Company Profiles

• 30.1. Keytruda Market Competitive Landscape
• 30.2. Keytruda Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Services Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Roche Holding AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck & Co. Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbVie Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Keytruda Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Novartis AG
• 31.3. AstraZeneca PLC
• 31.4. Bristol-Myers Squibb Company
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Gilead Sciences Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Biogen Inc.
• 31.10. Chugai Pharmaceutical Co. Ltd.
• 31.11. BioNTech AG
• 31.12. Organon Co.
• 31.13. Ono Pharmaceutical Co. Ltd.
• 31.14. Samsung Bioepis Co. Ltd.
• 31.15. Fate Therapeutics Inc.

32. Global Keytruda Market Competitive Benchmarking

33. Global Keytruda Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Keytruda Market

35. Keytruda Market Future Outlook and Potential Analysis

• 35.1 Keytruda Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Keytruda Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Keytruda Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer